Fig. 1From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adultsSubject disposition. IIV4-I, quadrivalent inactivated influenza vaccine manufacturing by investigational process; IIV4, licensed quadrivalent inactivated influenza vaccine; AE, adverse event; SAE, serious adverse event; PP, per-protocolBack to article page